Summary. Since patients with AIDS may receive fluoroquinolones concurrently with zidovudine, the antibacterial interaction of these drugs was investigated. No evidence was found of antagonism between zidovudine and ciprofloxacin, DR-3355, enoxacin, lomefloxacin or ofloxacin against enterobacteria, staphylococci or Pseudomonas aeruginosa. Furthermore, the bactericidal activity of the fluoroquinolones against selected enterobacteria in nutrient broth was not affected by a clinically achievable concentration of zidovudine. It seems unlikely that zidovudine will have an adverse effect on the antibacterial activity of the fluoroquinolones in patients with AIDS.
Introduction
Zidovudine (3'-azido-3'-deoxythymidine ; Retrovir, AZT) is a thymidine analogue that inhibits the reverse transcriptase of human immunodeficiency virus (HIV)'*2 and is useful, therefore, in the treatment of the acquired immune-deficiency syndrome (AIDS). 3 In addition to its antiviral activity, zidovudine is active against members of the Enterobacteriaceae because of its incorporation into bacterial DNA. This causes chain termination because the azido group makes subsequent 3'-5'-phosphodiester linkages imp~ssible.~-~ The fluoroquinolones are bactericidal, oral, nontoxic, broad-spectrum antibacterial agents7 * useful for the treatment of opportunistic bacterial infections that often occur in AIDS patients.'-13 These patients may be given a fluoroquinolone concurrently with zidovudine; because both drugs act on bacterial DNA synthesis, zidovudine may affect the antibacterial activity of the fluoroquinolones. The potential interactions between zidovudine and the fluoroquinolones were investigated in enterobacteria, which are susceptible to zidovudine, and in staphylococci and Pseudomonas aeruginosa, which are intrinsically resistant to z i d o v~d i n e .~~~ The effect of zidovudine on the activity of ciprofloxacin, DR-3355, enoxacin, lomefloxacin and ofloxacin against both laboratory and clinical strains was investigated by determination of minimum inhibitory concentrations (MIC). This measures only the inhibition of bacterial multiplication by the 4-quinolones' and does not provide information about the bactericidal activity of the drug. Indeed, drugs, which on the basis of their MIC do not show any interaction with the 4-quinolones, can affect their bactericidal a c t i v i t i e~.~? '~ Therefore, the bactericidal activity of the drug combination against selected strains of enterobacteria was also investigated because this is especially important in neutropenic patients.
Materials and methods

Drugs
Ciprofloxacin (Bayer, UK), DR-3355 (Daiichi Pharmaceutical Co., Japan) and zidovudine (Wellcome, UK) were dissolved in sterile distilled water. Enoxacin (ParkeDavis, UK), lomefloxacin (Searle, UK) and ofloxacin (Hoechst, UK) were dissolved in 0.5 M NaOH 0.02 ml/ mg before the appropriate concentration was prepared in sterile distilled water.
Bacterial strains
The laboratory strains Escherichia coli KLl6, l 5 Salmonella typhimurium NCTC57 10, P . aeruginosa CP, Staphylococcus aureus E3T and Staph. epidermidis SK360I6 were used. Twelve clinical isolates (1 E. coli, 4 Salmonella, 4 P . aeruginosa and 3 staphylococci) were obtained from R. Paton of the Royal Infirmary, Edinburgh. Colonies taken from drug-free nutrient agar were used to inoculate the overnight cultures used in these experiments.
Measurement of minimum and fractional inhibitory concentrations
MICs were determined with an arithmetic dilution scheme with the following progression: 1, 1.5,2, 3, 4, 5, 7.5. MICs and fractional inhibitory concentrations(F1Cs) were determined in Nutrient Agar (Oxoid) with an inoculum of lo4 cfu. The MIC was taken to be the lowest drug concentration that inhibited bacterial growth after overnight incubation at 37°C. The FIC was taken as the proportion of the MIC of the test drug, in the presence of the other, that gave no visible growth and the FIC index was the sum of the FICs of the two drugs at maximum interaction. An FIC index of <0.7 was considered to indicate synergy, 0.7-< 1.5 as additive activity, 1-5-2 as indifference and > 2.0 as antagonism.
Measurement of bactericidal eflects
The bactericidal activity of the fluoroquinolones in nutrient broth at a range of concentrations alone and in the presence of zidovudine 1 mg/L was determined as previously described. Percentage survival after incubation for 3 h at 37°C was estimated by viable counting on nutrient agar.
Results
All 17 strains (five laboratory and 12 clinical) examined were susceptible to the five fluoroquinolones (tables I and 11). The seven enterobacteria were also susceptible to zidovudine (MICs 0.15-1.5 mg/L) (table I). The 10 strains of P . aeruginosa and the staphylococci examined were intrinsically resistant to zidovudine, with MICs > 500 mg/L (table 11) .
Chess-board assays for the interaction of zidovudine and fluoroquinolones could not be done with the staphylococci and P . aeruginosa because of their resistance to zidovudine. Therefore, the MICs of the five fluoroquinolones for these organisms were determined in the presence of a single concentration (1 mg/L) of zidovudine. Table I11 shows the ratio of the MIC of the fluoroquinolone in the presence of zidovudine 1 mg/L to the MIC of the 4-quinolone alone. It can be seen that, in most cases, the addition of zidovudine 1 mg/L had little or no effect, with the ratios of the MICs in the range 0.75-1 -5. Lomefloxacin was an exception; the ratios of the MICs with this drug were between 1-5 and 2.5, indicating a slight increase of the MIC in the presence of zidovudine.
The interactions between the fluoroquinolones and zidovudine were investigated by chess-board titration with organisms susceptible to zidovudine and FIC indices were calculated. In most cases, the FIC index of the combination was c 1 (table IV). The mean of the seven FIC indices for each drug ranged from 0.59 for ofloxacin to 0.88 for DR-3355 indicating either additive activity or weak synergy. It is interesting that, whereas ofloxacin had the lowest mean FIC, DR-3355, the S-(-)-isomer of ofloxacin, had the highest. Laboratory strain E. coli KL16, appeared to behave differently from the other strains. Its FIC indices for the interaction of the five quinolones with zidovudine ranged from 0-75 to 1-5, slightly higher than those observed with the other strains tested (table IV) . However, even with this strain, the interaction between zidovudine and the fluoroquinolones ranged from additive activity to indifference and showed no antagonism. Thus, MIC measurements showed no evidence of any negative interactions between the fluoroquinolones and zidovudine against either zidovudine-susceptible or -resistant bacteria. The effect of zidovudine 1 mg/L on the bactericidal activity of the fluoroquinolones against E. coli KL16 and S. typhimurium NCTC 5710 in nutrient broth was investigated. Figs. 1 and 2 show that addition of zidovudine to ciprofloxacin at concentrations of 0-015-9 mg/L slightly increased the bactericidal activity of the 4-quinolone against E. coli KL16 and S. typhimurium NCTC 5710 over the 3-h period of exposure. Similarly, zidovudine slightly increased the bactericidal activities of DR-3355, enoxacin, lomefloxacin and ofloxacin at concentrations from 0.015 mg/L to 9 mg/L against both strains in nutrient broth (results not shown). Hence, zidovudine does not appear to affect the bactericidal activity of the fluoroquinolones because the bactericidal activity of five of these drugs against these strains was unaffected by zidovudine at its maximum clinically achievable plasma concentration. The combination of zidovudine with each of the five fluoroquinolones was essentially additive against the enterobacteria tested, although ofloxacin showed weak synergy as the mean FIC was <0.7. The significance of this weak synergy must be questioned because, with DR-3355, the S-(-)-isomer of ofloxacin, the combination was merely additive. Hence, in terms of MIC there is little interaction between the 4-quinolones and zidovudine. Furthermore, the bactericidal activities of the fluoroquinolones were slightly greater against E. coli KL16 and S. typhimurium NCTC 5710 in the presence of zidovudine at its maximum clinically achievable concentration. Therefore, the bactericidal activity of the fluoroquinolones, which is of particular relevance in AIDS patients, is unaffected by zidovudine. As the fluoroquinolones are used for treating salmonella bacteriaemia in AIDS patients,'g' l~~ the observation that little interaction occurs between zidovudine and the fluoroquinolones with this genus is especially significant.
Despite the fact that zidovudine and fluoroquinolones interfere with bacterial DNA synthesis, very little synergy was displayed either in terms of killing activity or inhibition of bacterial multiplication. Nevertheless, it seems worthwhile to investigate the interactions of antimicrobials used for treating infections in AIDS patients with zidovudine be-
